Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older and are able to understand and sign a consent form agreeing to take part in the study
• People who have been newly diagnosed with multiple myeloma and have not yet received any treatment for it, with the diagnosis confirmed according to standard international criteria
• People whose multiple myeloma shows measurable levels of abnormal proteins in the blood (M-protein of 1 g/dL or more, or specific light chain levels above a defined threshold with an abnormal ratio)
• People who are classified as "frail" according to a specific international myeloma frailty scoring tool (confirm with trial site)
• People whose blood test results fall within the ranges required by the trial
• People who are capable of having children and who agree to use adequate contraception from the time of signing the consent form until at least 3 months after the last dose of the study drug

Who may not be able to join:

• People whose myeloma does not produce measurable proteins in the blood, or where measurable disease is only detectable in urine or as tumour masses (plasmacytomas)
• People whose myeloma has spread to the brain or spinal cord
• People with significant lung or breathing problems
• People who have had a stroke, mini-stroke, or seizure within the past 6 months
• People with a currently active serious infection (such as bacterial, viral, or fungal) that requires treatment with antimicrobial medicines
• People who have HIV or active hepatitis infection
• People with a history of another cancer that is considered at high risk of coming back and may need treatment, or another cancer that was previously treated with chemotherapy that is still affecting the bone marrow — or people with any other currently active cancer (meaning it has been progressing or required a change in treatment within the last 24 months)
• People with an active autoimmune disease that has required immune-suppressing medication within the past 6 months
• People who have a known severe allergy or intolerance to any of the study drugs or their ingredients
• People who have had extensive radiotherapy within the past 14 days, or any focused radiation within the past 7 days
• People who are currently receiving or have recently received treatment for multiple myeloma, or who have taken high-dose steroid medicines (above a specified threshold) within the 14 days before the trial starts
• People who have received a live vaccine within the past 4 weeks (non-live vaccines, including COVID-19 vaccines, are generally permitted)
• People who have recently taken certain medications known to strongly interact with liver enzymes (strong CYP3A4 inducers), or who have used St. John's Wort supplement within a defined period before starting the trial (confirm timeframe with trial site)
• People who have had major surgery or a significant injury within the past 2 weeks (note: certain spinal procedures such as kyphoplasty or vertebroplasty are not considered major surgery for this purpose)
• People who have taken part in another clinical drug trial or used an investigational medical device within the past 4 weeks or within 5 half-lives of the investigational drug (whichever is longer), or who are currently enrolled in another active interventional trial
• People with other significant medical or mental health conditions — such as uncontrolled diabetes, severe dementia, or substance misuse — that could interfere with the trial or pose a risk to the person's safety
• People with any other condition or circumstance that, in the treating doctor's judgement, would make participation unsafe, not in the person's best interest, or would interfere with the trial assessments

Important: Always verify eligibility with the trial site directly before applying.